Navigation Links
TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
Date:12/10/2007

in the patients treated with bendamustine was 18.9 months compared to 6.1 months for those patients treated with chlorambucil. Bendamustine demonstrated a manageable tolerability profile. As would be expected of a chemotherapeutic agent the most common adverse events included myelosuppression, nausea, fatigue, diarrhea, vomiting and fever; the most common serious adverse events were febrile neutropenia and pneumonia.

"If approved, we believe TREANDA will be an important new treatment option for patients with CLL," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "Based on these study results and other data on bendamustine being presented at ASH, we envision TREANDA as the foundation of our growing oncology portfolio."

About the Phase 3 Study Design

The randomized, international, multicenter, open-label Phase 3 clinical trial evaluated the safety and efficacy of bendamustine compared to chlorambucil in previously untreated patients with B-CLL Binet stage B/C [equivalent to Rai stages I-IV], a measure of disease progression (n=305). Patients received bendamustine (100 mg per meters squared on days 1+2) (n=156) or chlorambucil (0.8 mg/kg on days 1+15) (n=149) for up to six treatment cycles. Safety and efficacy were assessed by an Independent Data Monitoring Committee.

About TREANDA (bendamustine HCl)

TREANDA is a novel chemotherapeutic agent, a hybrid of a purine analog and an alkylator. Preclinical data demonstrate that TREANDA acts in two distinct ways to kill cancer cells. TREANDA damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect of TREANDA may be attributable to its unique chemical design.

The FDA granted priority review to the new drug application (NDA) for TREANDA for the treatment
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
7. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
8. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Incorporated,(Nasdaq: VICL ) today announced the receipt ... from AnGes MG, Inc., under a previously announced,collaborative ... Phase 3 metastatic melanoma trial. Through a series ... $15.3 million to date,of the $22.6 million total ...
... vaccine induced neutralizing antibodies against widely divergent ... Baxter International,Inc. (NYSE: BAX ) announced publication ... England Journal of Medicine (NEJM) of data demonstrating ... I/II trial,endpoints for safety and immunogenicity (generating a ...
Cached Medicine Technology:Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... RANCHO CORDOVA, Calif., March 9 ... program announced it helped the 500,000th child since ... almost $100 million in free eyecare and eyewear ... http://www.newscom.com/cgi-bin/prnh/20090309/SF80394 )Sight for Students started as ...
... Usage Trends and Growing Uninsured Population Raise Concerns ... Report from HealthLeaders-InterStudy NASHVILLE, Tenn., March 9 ... market intelligence, reports that through the first three ... health insurers saw on average a 25 percent ...
... with therapy if subjects are willing and motivatedANN ARBOR, Mich., ... raised in an upper-middle class suburb, she felt a deep ... basement where she rode her Big Wheel at age 3 ... 8.As years went by, the home,s empty spaces disappeared, replaced ...
... Nu Skin Presents Findings at Asian Societies of Cosmetic ... a newly identified internal free radical generator, age-related NOX ... (NYSE: NUS ) links the enzyme to ... The research was presented at the 9th Scientific Conference ...
... Philanthropist and Renowned Chef Art Smith Creates Oat-Inspired Menu ... In Times Square today, Quaker announces ... purpose movement powered by Quaker and the human energy ... lives every day with the wholesome goodness of whole-grain ...
... wireless customer relationship management (CRM) experts, today ... and compliance software solution. iComply helps companies ... email for improved compliance with government regulations, ... The software is offered with a Lotus ...
Cached Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 2Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 3Health News:Compulsive Hoarding Poses Safety and Psychological Risks 2Health News:Compulsive Hoarding Poses Safety and Psychological Risks 3Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 2Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 4Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 5Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 2Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 3
... Peg electrodes typically are positioned ... enable epidural recording of brain ... and are furnished in several ... thicknesses. A 4.6 mm twist ...
... cortical strip electrodes are extra thin ... through a burr hole. The narrow ... enables quick and secure attachment to ... Integra Epilepsy electrode designs, they are ...
... John R. Gates and Mary E. Dunn ... are designed for reliability, safety and ease ... electrodes, platinum contacts are mounted flush with ... have larger exposures. Strip and depth electrodes ...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
Medicine Products: